Physician profile
Robert Andina
NPI 1346235280
$4,592.73
in general payments reported to CMS, 2019-2025
22 companies · $779 in 2025
The $779 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $223 · 2021: $678 · 2022: $752 · 2023: $387 · 2024: $816 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $799.16 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $677.26 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amgen INC. | $655.55 | 2019-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $576.36 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $418.79 | 2021-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $375.71 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $258.20 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $170.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $144.00 | 2020-2022 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Amarin Pharma, INC. | $107.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $64.12 | 2019-2020 | |
| Exact Sciences Corporation | $32.90 | 2025 | Cologuard Collection Kit |
| Ionis Pharmaceuticals, INC. | $26.35 | 2025 | Tryngolza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.47 | 2024 | Entyvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.13 | 2023 | Arexvy, Shingrix |
| Lantheus Medical Imaging, INC. | $21.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.06 | 2019 | |
| Edwards Lifesciences Corporation | $20.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2025 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $15.96 | 2019 | |
| Allergan, INC. | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Andina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.